Journal Mobile Options
Table of Contents
Vol. 69, No. 2, 2005
Issue release date: September 2005
Section title: Clinical Study
Oncology 2005;69:130–134
(DOI:10.1159/000087815)

A Phase II Trial of Gemcitabine, 5-Fluorouracil and Leucovorin in Advanced Esophageal Carcinoma

Morgan-Meadows S. · Mulkerin D. · Berlin J.D. · Kim K. · Bailey H. · Saphner T. · Jumonville A. · Hansen R. · Ahuja H. · McFarland T. · Thomas J.P.
aUniversity of Wisconsin Comprehensive Cancer Center, Madison, Wisc., bVanderbilt University, Nashville, Tenn., cGreen Bay Oncology, Green Bay, Wisc., dGunderson Clinic, Ltd., La Crosse, Wisc., eOconomowoc Memorial Hospital, Oconomowoc, Wisc., fWausau Hospital, Wausau, Wisc., and gUW Health Oncology and Hematology, Madison, Wisc., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: 10/20/2004
Accepted: 2/26/2005
Published online: 9/21/2005

Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 2

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL

Abstract

Background: The aim of this study was to evaluate the overall response rate, toxicity and overall survival in patients with locally advanced or metastatic esophageal cancer treated with gemcitabine, 5-fluorouracil (5-FU) and leucovorin. Patients and Methods: Patients with either adenocarcinoma or squamous cell carcinoma of the esophagus could enroll; however, patients could not have received prior chemotherapy for metastatic disease. Treatment cycles consisted of infusions of all three agents at days 1, 8 and 15, repeated every 28 days. Patients received gemcitabine 1,000, leucovorin 25 and 5-FU 600 mg/m2. Tumor assessment was performed every 2 cycles. Responses were assessed using the Eastern Cooperative Oncology Group solid tumor response criteria. Results: Thirty-five patients with metastatic or locally advanced esophageal cancer enrolled. One complete response and ten partial responses were observed for an overall response rate of 31.4%. An additional 11 patients had stable disease as their best response. The median survival was 9.8 months with a 1-year survival rate of 37.1%. Toxicity was predominately hematologic, with 58% of patients experiencing grade 3 or 4 neutropenia. Conclusion: The combination of gemcitabine, 5-FU and leucovorin had activity in advanced esophageal cancer. Patients tolerated the regimen well, with myelosuppression occurring most commonly. The combination merits further investigation as a treatment for esophageal cancer.


  

Author Contacts

Sherry Morgan-Meadows, MD
600 Highland Ave K6/5
Madison, WI 53792 (USA)
Tel. +1 608 283 5781, Fax +1 608 265 8133
E-Mail slm@medicine.wisc.edu

  

Article Information

Received: October 20, 2004
Accepted after revision: February 26, 2005
Published online: August 23, 2005
Number of Print Pages : 5
Number of Figures : 2, Number of Tables : 2, Number of References : 17

  

Publication Details

Oncology (International Journal of Cancer Research and Treatment)

Vol. 69, No. 2, Year 2005 (Cover Date: Released September 2005)

Journal Editor: Trump, D.L. (Buffalo, N.Y.)
ISSN: 0030–2414 (print), 1423–0232 (Online)

For additional information: http://www.karger.com/ocl


Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: 10/20/2004
Accepted: 2/26/2005
Published online: 9/21/2005

Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 2

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.